Clinical Physiology of Circulation

Chief Editor

Leo A. Bockeria, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, President of Bakoulev National Medical Research Center for Cardiovascular Surgery


Влияние генетических факторов на концентрацию клопидогреля в плазме крови у больных с сердечно-сосудистой патологией

E-mail: Сведения доступны для зарегистрированных пользователей.

Link: Clinical Physiology of Blood Circulaiton. 2010; (): -

Download
Full text:  

Abstract

The work objective was the study of CYP2C19, MDR1 and P2Y12 polymorphism genes influence on concentration of active metabolite clopidogrelum in patients blood plasma with cardiovascular pathology. 26 patients with ischemic disease and ischemic stroke were evaluated. Genotypes on the points of polymorphism were determined by the method of minisequencing with the following MALDI-TOF mass-spectrometry. The concentration of clopidogrelum metabolite in plasma was measured using chromatography- mass-spectometric quantitative analysis. The association of functional defective alleles 2* and 3* of CYP2C19 gene with the concentration of active metabolite clopidogrelum in plasma was revealed. The concentration was lower in patient with 1*/2* and 1*/3* genotypes in comparison with patients with 1*/1* (0,23±0,09 vs 1,12±0,93; p=0,013 for CYP2C19*2 and 0,27±0,16 vs 1,10±0,94; p=0,014 for CYP2C19*3). There was no significant relation between polymorphous markers C3435T gene MDR1 and T744C gene P2Y12, and the concentration of clopidogrelum in plasma. Thus, allelic variants of CYP2C19 gene can be involved in the development of resistance to clopidogrelum.

 If you found mistakes, select text and press Alt+A